Citations

Mayo Clinic

Showing 10 of 108523 citations.

CT and MR Imaging of Intracranial Tuberous Sclerosis
Houser, O. Wayne, Gómez, Manuel R.

The Journal of Dermatology | April 10, 2015 | Volume: 19 | Issue: 11 | Pages: 904-908

10.1111/j.1346-8138.1992.tb03803.x | PMID 1293181 Get It

AbstractCT and MR have permitted radiology to play a greater, but not definitive, role in detecting the pathologic components of tuberous sclerosis. SEN may be identified in only 80% of patients. Tubers are more ubiquitous and readily identified by MR in children and adults when the brain is myelinated. Since tubers are predominately peripheral hypomyelinated lesions, the detection of small lesions may be delayed until an infant is over 16–18 months of age when the myelin will have extended to the junction between the cortical white and gray matter. SEGA typically evolve later during the first and second decades of life. Successful genetic counseling implies a need to detect tuberous sclerosis at a stage during infancy when imaging may fail to confirm the diagnosis, so tuberous sclerosis remains a clinical diagnosis.
The Neuropathology of Tuberous Sclerosis
Scheithauer, Bernd W.

The Journal of Dermatology | April 10, 2015 | Volume: 19 | Issue: 11 | Pages: 897-903

10.1111/j.1346-8138.1992.tb03802.x | PMID 1293180 Get It

AbstractTuberous sclerosis, an autosomal dominant disorder associated with hamartomas in multiple organs, prominently affects the central nervous system; principle lesions include subependymal nodules and giant cell astrocytomas, white matter heterotopias, and cortical tubers. Histologic, immunocytochemical, and ultrastructural features of these processes suggest they have their basis in abnormal cell migration and differentiation. Aberrant expression of cystoskeletal proteins appears to be common to the multisystem hamartomas of this disorder and may, in part, underlie their pathogenesis.
The Tuberous Sclerosis Complex, A Prototype of Hamartiosis and Hamartomatosis
Gómez, Manuel R.

The Journal of Dermatology | April 10, 2015 | Volume: 19 | Issue: 11 | Pages: 892-896

10.1111/j.1346-8138.1992.tb03801.x | PMID 1293179 Get It

Management and outcomes of pituitary apoplexy
Singh, Tarun D. , Valizadeh, Navid , Meyer, Fredric B. , Atkinson, John L. D., Erickson, Dana , Rabinstein, Alejandro A.

Journal of Neurosurgery | April 10, 2015 | Volume: 122 | Issue: 6 | Pages: 1450-1457

10.3171/2014.10.jns141204 | PMID 25859804 Get It

OBJECT This study was undertaken to analyze the predisposing factors, clinical presentation, therapeutic management, and clinical recovery in patients with pituitary apoplexy, with an emphasis on the long-term visual, endocrine, and functional outcomes. METHODS The authors performed a retrospective analysis of consecutive cases involving patients treated at Mayo Clinic between 1992 and 2013. Patients were included in the study only if they had 1) abrupt onset of severe headache or visual disturbance in the presence of a pituitary adenoma and 2) radiological or surgical confirmation of a pituitary mass. The primary endpoints of analysis were the visual (ocular motility, visual fields, and visual acuity), endocrine, and functional outcomes (using the modified Rankin Scale). RESULTS Eighty-seven patients were identified (57 males and 30 females, mean age 50.9 years, range 15–91 years). Twenty-two patients (25.3%) had a known pituitary adenoma. Hypertension was the most common associated factor (39%). Headache was the most frequent presenting symptom (89.7%), followed by visual abnormalities (47.1%). Cranial nerve palsies were present in 39% and visual field defects in 34.1%. MRI detected hemorrhage in 89% patients, as compared with 42% detected by CT scan. Sixty-one patients (70.1%) underwent surgery during acute hospitalization (median time from apoplexy 5 days, IQR 3–10 days), 8 (9.2%) had delayed surgery, and 18 (20.7%) were treated conservatively. Histopathological examination revealed adenoma with pure necrosis in 18 (30%), pure hemorrhage in 4 (6.7%), and both in 6 (10%) patients. Four patients died during hospitalization. The average duration of follow-up was 44.2 ± 43.8 months. All survivors were independent and had complete resolution or substantial improvement in eye movements and visual fields at the last follow-up. Many patients needed long-term hormonal replacement with levothyroxine (62.7%) and cortisol (60%). Daily desmopressin was needed in 23% of all surgical patients at 3 months (versus none of the medically treated) and this requirement decreased slightly over time. Regrowth of pituitary adenoma was seen in 7 patients (8.6%). There were no statistically significant differences in any of the outcome measures across the treatment groups. CONCLUSIONS The outcome of most patients with pituitary apoplexy is excellent. Selected patients can be managed conservatively, and patients with severe neuro-ophthalmological deficits treated with early surgery can achieve an excellent recovery.
Histopathologic Study of Cutaneous Lesions in Behçet's Syndrome
Chun, Soo Il , Su, W. P. Daniel , Lee, Sungnack, Lee, Sungnack

The Journal of Dermatology | April 10, 2015 | Volume: 17 | Issue: 6 | Pages: 333-341

10.1111/j.1346-8138.1990.tb01653.x | PMID 2384635 Get It

An anatomic explanation for combined so‐called adventitial/intraneural cysts
Prasad, Nikhil K. , Howe, Benjamin M. , Amrami, Kimberly K. , Spinner, Robert J.

Clinical Anatomy | April 10, 2015 | Volume: 28 | Issue: 7 | Pages: 829-832

10.1002/ca.22538 | PMID 25864719 Get It

Inflammation and the depot-specific secretome of human preadipocytes
Zhu, Yi , Tchkonia, Tamar , Giorgadze, Nino, Wang, Libing, Li, Peter W., Heppelmann, Carrie J. , Bouloumié, Anne , Jensen, Michael D. , Bergen, H. Robert, Kirkland, James L. , Stout, Michael B , Tchkonia, T , Zhu, Yi

Obesity | April 10, 2015 | Volume: 23 | Issue: 5 | Pages: 989-999

10.1002/oby.21053 | PMID 25864718 Get It

Plasma Protein Abnormalities and Vascular Lesions
Pittelkow, Mark R.

The Journal of Dermatology | April 10, 2015 | Volume: 24 | Issue: 11 | Pages: 732-733

10.1111/j.1346-8138.1997.tb02526.x | PMID 9433031 Get It

Polysialic acid as an antigen for monoclonal antibodyHIgM12 to treat multiple sclerosis and other neurodegenerative disorders
Watzlawik, Jens O. , Kahoud, Robert J., Ng, Shermayne, Painter, Meghan M. , Papke, Louisa, Zoecklein, Laurie, Wootla, Bharath , Warrington, Arthur E. , Carey, William A., Rodriguez, Moses , Ng, Sher May , Papke, Louisa M, Wootla, Bharath , Rodriguez, Moses , Watzlawik, Jens O

Journal of Neurochemistry | April 10, 2015 | Volume: 134 | Issue: 5 | Pages: 865-878

10.1111/jnc.13121 | PMID 25866077 Get It

AbstractCNSregeneration is a desirable goal for diseases of brain and spinal cord. Current therapeutic strategies for the treatment of multiple sclerosis (MS) aim to eliminate detrimental effects of the immune system, so far without reversing disability or affecting long‐term prognosis in patients. Approachable molecular targets that stimulateCNSrepair are not part of the clinical praxis or have not been identified yet. The purpose of this study was to identify the molecular target of the human monoclonal antibodyHIgM12.HIgM12 reverses motor deficits in chronically demyelinated mice, a model ofMS. Here, we identified polysialic acid (PSA) attached to the neural cell adhesion molecule (NCAM) as the antigen forHIgM12 by using differentNCAMknockout strains and throughPSAremoval from theNCAMprotein core. Antibody binding toCNStissue and primary cells, antibody‐mediated cell adhesion, and neurite outgrowth onHIgM12‐coated nitrocellulose was detected only in the presence ofPSAas assessed by western blotting, immunoprecipitation, immunocytochemistry, and histochemistry. We conclude thatHIgM12 mediates it'sin vivoandin vitroeffects through binding toPSAand has the potential to be an effective therapy forMSand neurodegenerative diseases.imageThe human antibody HIgM12 stimulates neurite outgrowthin vitroand promotes function in chronically demyelinated mice, a model of multiple sclerosis. The cellular antigen for HIgM12 was undetermined. Here, we identified polysialic acid attached to NCAM (neural cell adhesion molecule) as the cellular target for HIgM12. This includes glial fibrillary acidic protein (GFAP)‐positive mouse astrocytes (GFAP, red; HIgM12, green; DAPI, blue) among other cell types of the central nervous system. These findings indicate a new strategy for the treatment of neuro‐motor disorders including multiple sclerosis.
Late Onset Hyalinosis Cutis et Mucosae
Su, W. P. Daniel , Wang, P, Eto, Hikaru, Hashimoto, Ken

The Journal of Dermatology | April 10, 2015 | Volume: 27 | Issue: 7 | Pages: 425-433

10.1111/j.1346-8138.2000.tb02200.x | PMID 10935338 Get It

AbstractTwo cases of non‐familial, late onset (50 and 62‐years‐old) hyalinosis cutis et mucosae were studied and compared with classical early onset cases. Late onset cases showed essentially the same histological and ultrastructural features described for early onset cases. The late onset variety should be distinguished from other diseases; they resemble systemic amyloidosis and sometimes the adult form of colloid milium.